Who benefits from PBMs? Federal regulators scrutinize drug middlemen
BY Blinn E. Combs, Esq. and Michael R. Alexander, Esq., Brown & Fortunato, P.C. On July 9, the Federal Trade Commission (“FTC”) released an Interim Staff Report (“Report”) stating that Pharmacy Benefit Managers drive up drug costs. The Report, which details a two-year investigation into the market power of PBMs, has already prompted congressional action. The House Committee on Oversight and Accountability, which released its own contemporaneous PBM report, held a hearing on July...











